HC Wainwright Analysts Give Pieris Pharmaceuticals, Inc. (PIRS) a $9.00 Price Target
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has been assigned a $9.00 price objective by equities researchers at HC Wainwright in a report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 94.38% from the stock’s previous close.
Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Rodman & Renshaw initiated coverage on shares of Pieris Pharmaceuticals in a research report on Tuesday, May 30th. They set a “buy” rating and a $9.00 target price for the company. Finally, TheStreet raised shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Wednesday, May 3rd. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $8.25.
Pieris Pharmaceuticals (PIRS) opened at 4.63 on Friday. The company’s 50-day moving average is $5.35 and its 200 day moving average is $3.55. The company’s market cap is $199.40 million. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $6.20.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by $0.35. The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 459.73% and a negative return on equity of 123.78%. On average, equities analysts predict that Pieris Pharmaceuticals will post ($0.70) EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $132,000. Creative Planning increased its stake in Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock worth $156,000 after buying an additional 13,700 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $162,000. Rhumbline Advisers purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $184,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Pieris Pharmaceuticals during the second quarter worth $292,000. 44.88% of the stock is owned by institutional investors and hedge funds.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.